Parkinson’s disease, a relentless neurodegenerative condition impacting over a million individuals in the United States and an estimated ten million globally, presents a complex constellation of debilitating symptoms. These manifest as involuntary tremors, significant challenges in motor control, disrupted sleep patterns, and a progressive decline in cognitive faculties. While current therapeutic strategies, encompassing long-term pharmacological interventions and invasive procedures like deep brain stimulation (DBS), offer some alleviation of symptoms, they fall short of halting the disease’s inexorable march or providing a definitive cure.
A groundbreaking collaborative effort, spearheaded by China’s Changping Laboratory in conjunction with Washington University School of Medicine in St. Louis and several other esteemed international institutions, has illuminated a distinct neural circuit implicated in the core manifestations of Parkinson’s disease. This extensive research has pinpointed the somato-cognitive action network, or SCAN, as a pivotal player in the pathophysiology of this disorder. Remarkably, when this specific network was precisely targeted using a non-surgical experimental methodology known as transcranial magnetic stimulation (TMS), patients exhibited more than double the symptomatic improvement compared to instances where stimulation was directed at adjacent brain regions.
These pivotal findings, disseminated on February 4th in the prestigious journal Nature, represent a significant departure from established understandings of Parkinson’s disease, heralding a new paradigm for the development of more refined and precisely directed therapeutic interventions. Dr. Nico U. Dosenbach, a co-author of the study and the David M. & Tracy S. Holtzman Professor of Neurology at WashU Medicine, articulated the profound implications, stating, "This work unequivocally demonstrates that Parkinson’s is fundamentally a disorder of the SCAN, and our data provide compelling evidence that by engaging the SCAN in a personalized and highly accurate manner, we can achieve significantly greater success in treating Parkinson’s than previously conceived." He further elaborated, "Modulating the activity within the SCAN holds the potential not only to alleviate symptoms but also to potentially decelerate or even reverse the progression of the disease itself."
The foundational concept of the SCAN was first elucidated by Dr. Dosenbach in a 2023 publication in Nature. This intricate network is situated within the motor cortex, the brain’s primary command center for orchestrating voluntary movements. Its crucial function involves the seamless translation of intended actions into tangible physical execution and the subsequent real-time monitoring of these actions. Given that Parkinson’s disease extends its influence far beyond motor deficits, affecting vital functions such as digestion, sleep regulation, motivation, and cognitive processes, senior author Dr. Hesheng Liu recognized the imperative to investigate whether dysregulation within the SCAN could account for this expansive spectrum of symptoms and concurrently serve as a viable therapeutic target.
To rigorously test this hypothesis, Dr. Liu’s research team undertook an exhaustive analysis of neuroimaging data drawn from a cohort exceeding 800 participants. This diverse group was assembled from multiple research centers across both the United States and China, and included individuals diagnosed with Parkinson’s disease who were undergoing various treatments, including DBS, transcranial magnetic stimulation, focused ultrasound, and pharmacological therapies. For comparative analysis, the study also incorporated data from healthy volunteers and individuals presenting with other movement disorders.
The comprehensive analysis revealed a distinct pattern of aberrant brain connectivity in individuals with Parkinson’s disease, characterized by excessive functional coupling between the SCAN and the subcortex, a deep brain structure integral to emotional processing, memory formation, and motor control. Across all four therapeutic modalities evaluated in the study, the efficacy of treatment was directly correlated with the reduction of this heightened connectivity. The restoration of a more balanced interplay between these neural regions was instrumental in normalizing the activity within the brain circuits responsible for the planning and intricate coordination of motor actions.
"For many decades, Parkinson’s disease has been predominantly understood through the lens of motor impairments and the involvement of the basal ganglia, the brain region primarily responsible for regulating muscle movements," Dr. Liu explained. "Our research fundamentally challenges this narrow perspective, demonstrating that the disease originates from a far more pervasive network dysfunction. The SCAN exhibits heightened connectivity with key regions demonstrably associated with Parkinson’s disease, and this abnormal neural wiring is not only responsible for motor deficits but also profoundly impacts related cognitive and autonomic functions."
Building upon these profound insights, the research consortium devised an innovative precision treatment system engineered to precisely target the SCAN without the need for surgical intervention, achieving an unprecedented millimeter-level accuracy. This pioneering approach leverages transcranial magnetic stimulation, a non-invasive technique that delivers controlled magnetic pulses to specific brain areas via a device positioned externally on the scalp. In a meticulously conducted clinical trial involving 18 patients who received SCAN-targeted stimulation, an impressive 56% demonstrated a positive response after just two weeks of treatment. In stark contrast, only 22% of a comparable group of 18 patients who received stimulation directed at nearby brain regions experienced improvement, underscoring the SCAN-targeted approach’s more than 2.5-fold increase in effectiveness.
"A significant advantage of non-invasive treatments is the potential to initiate neuromodulatory interventions at a much earlier stage of the disease compared to current practices with DBS, as they circumvent the necessity for brain surgery," Dr. Dosenbach emphasized, highlighting the practical clinical implications of this advancement.
He further cautioned that while these findings are exceptionally promising, more foundational research is still requisite to fully elucidate the specific contributions of different components within the SCAN to the diverse array of Parkinson’s symptoms.
Looking towards the future, Dr. Dosenbach is spearheading the launch of new clinical trials in collaboration with Turing Medical, a startup company co-founded by WashU Medicine. These forthcoming studies are designed to rigorously evaluate a novel non-invasive therapy that utilizes surface electrode strips placed over SCAN regions to specifically address gait abnormalities, a common and debilitating symptom experienced by individuals with Parkinson’s disease. Concurrently, he intends to explore the potential of low-intensity focused ultrasound as another non-invasive modality capable of modulating SCAN activity through the application of acoustic energy.
This groundbreaking research was generously supported by funding from the Changping Laboratory, the U.S. National Institutes of Health (grants MH096773, MH122066, MH121276, MH124567, NS129521, NS088590, R01NS131405, U01NS098969, and U01NS117836), the National Natural Science Foundation of China (grants 81527901, 81720108021, 81971689, 31970979, and 82090034), the National Key R&D Program of China (grant 2017YFE0103600), the Intellectual and Developmental Disabilities Research Center, the Kiwanis Foundation, the Washington University Hope Center for Neurological Disorders, and the Collaborative Innovation Center of Neuropsychiatric Disorders and Mental Health of Anhui Province (grant 2020xkjT05). It is important to note that the content presented herein is solely the responsibility of the authors and does not necessarily reflect the official viewpoints of the National Institutes of Health.
Several researchers involved in this study have disclosed potential conflicts of interest. Dr. H. Liu holds the position of chief scientist at Neural Galaxy Inc. Dr. L. Liu serves on the scientific advisory board for Beijing Pins Medical Co., Ltd and is listed as an inventor on patents and patent applications related to the deep brain stimulator utilized in this research. Dr. N.U.F. Dosenbach has a financial interest in Turing Medical Inc. and may derive financial benefit from the company’s successful marketing of FIRMM motion monitoring software, BullsAI neuromodulation targeting software, or PACE neuromodulation systems. Dr. E.M.G. and Dr. N.U.F. Dosenbach may receive royalty income derived from FIRMM technology, which was developed at Washington University School of Medicine and subsequently licensed to Turing Medical Inc. Dr. N.U.F. Dosenbach is also a co-founder of Turing Medical Inc. These potential conflicts of interest have undergone thorough review and are being actively managed by Washington University School of Medicine. Dr. S. Li is a consultant for Iota Biosciences. Dr. P.A.S. receives fellowship education support from Medtronic and Boston Scientific.
About the Author
